As the pharmaceutical industry advances toward low global warming potential (GWP) propellants like HFA152a and HFO1234ze(E), understanding material compatibility becomes critical, especially when it comes to leachables from common device components.
In a recent evaluation, a group of pulmonary experts at Kindeva assessed the extractable levels associated with various polybutylene terephthalate (PBT) suppliers in pressurized metered dose inhaler (pMDI) formulations containing ethanol and low-GWP propellants. The study was designed to simulate worst-case conditions and generate actionable insights for development teams reformulating with emerging propellant systems.
The findings reinforce the importance of careful material selection and formulation control during the transition to sustainable pMDI technologies:
- Propellant choice affects extractable levels
- Increasing ethanol concentration increases leachables
- PBT grade influences extractable output
- Oligomer presence may impact performance
Understanding the interactions between propellant, co-solvent and material grade is essential for ensuring product stability, safety and compliance as low-GWP formulations progress toward commercialization.
Curious about the full impact of propellant, ethanol and material selection on leachables? Explore the full poster presentation.
Connect with Kindeva to discover how our end-to-end expertise helps future-proof your low-GWP inhalation products by mitigating extractables risk and accelerating sustainable pMDI development.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Manufacturing more sustainable tomorrows for pulmonary care
The shift to more sustainable inhalers is gaining pace. As pressure grows to reduce their environmental impact, low-Global Warming Potential (GWP) propellants are becoming an important part of the future of metered dose inhaler (MDI) development. In this infographic, we explore the trends shaping that transition, and share how Kindeva is helping partners prepare for […]
Learn More
Parenteral precision: Annex 1-ready sterile fill finish by design
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]
Learn More
Beyond the bench: Aerosol analysis and the physics of MDI performance
Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]
Learn MorePowering every breath you give: Our world-class Loughborough site
Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies. Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities. Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global […]
Learn More
Parenteral capabilities overview
Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution. Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations. Why choose Kindeva for your parental program Large-scale sterile fill finish The Bridgeton site supports vial, cartridge and prefilled […]
Learn More
Navigating the green revolution: Why next-generation propellants are critical for pMDIs
The imperative to address climate change is reshaping industries worldwide, and pharmaceutical manufacturers are no exception. In respiratory medicine, the spotlight has fallen on pressurized metered-dose inhalers (pMDIs). While crucial for millions of patients, pMDIs harness propellants with a global warming potential (GWP) many times higher than CO2. This significant environmental footprint is a critical […]
Learn More
Where the propellants are greener: Inside the MDI facility of the future
As the pharmaceutical industry accelerates toward net-zero goals, inhalation therapies face unique scrutiny. Pressurized metered-dose inhalers (pMDIs) remain vital for millions of patients, yet their reliance on legacy propellants presents a sustainability challenge. To address this, Kindeva has established its UK headquarters and MDI Center of Excellence in Loughborough, a facility purpose-built to lead the […]
Learn More
Career journeys blog 4: Grace Guo
In this story, we meet Grace Guo, Manager of Client Portfolio Relationship Management, whose pathway at Kindeva has grown through clear communication, strategic thinking and a strong focus on people.
Learn More
The next leap in skin-based drug delivery: How dermal delivery platforms are transforming tomorrows for patients
Skin-based drug delivery is gaining attention as patients and healthcare systems look for treatments that support at-home administration and remove the need for needle-based injections. As this shift accelerates, developers are investing in technologies that improve usability without compromising performance. These platforms are opening new possibilities for therapies that rely on reliable, patient-preferred delivery. A […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.